Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay
The compatibility of fasted state simulated intestinal fluid (FaSSIF) in drug permeation studies employing the phospholipid vesicle-based permeation assay (PVPA) model was confirmed by a set of different integrity indicators. Neither calcein permeability nor electrical resistance were found signific...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 January 2012
|
| In: |
International journal of pharmaceutics
Year: 2012, Volume: 422, Issue: 1/2, Pages: 52-58 |
| ISSN: | 1873-3476 |
| DOI: | 10.1016/j.ijpharm.2011.10.026 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.ijpharm.2011.10.026 Verlag, Volltext: https://www.sciencedirect.com/science/article/pii/S0378517311009653 
|
| Author Notes: | Sarah Maud Fischer, Stephen Timothy Buckley, Wiebke Kirchmeyer, Gert Fricker, Martin Brandl |
| Summary: | The compatibility of fasted state simulated intestinal fluid (FaSSIF) in drug permeation studies employing the phospholipid vesicle-based permeation assay (PVPA) model was confirmed by a set of different integrity indicators. Neither calcein permeability nor electrical resistance were found significantly changed indicating unaffected barrier tightness. Furthermore, the release of phospholipid from the barriers in contact with FaSSIF was negligible, although sodium taurocholate disappeared from the donor - possibly due to transfer into the barrier. Visual examination of the barrier structure by confocal laser scanning microscopy (CLSM) revealed no changes. The model drugs, cimetidine, nadolol, ketoprofen and griseofulvin showed either slightly enhanced or unchanged permeability values in the presence of FaSSIF. This may be attributed to micellar encapsulation and/or slight changes in barrier characteristics. Particularly for poorly soluble drugs, FaSSIF appeared favourable in terms of markedly improved recovery. Moreover, utilisation of BSA in the receiver compartment seems to augment this beneficial effect on recovery rate. It is likely that this experimental set-up affords better sink conditions in the receiver phase, which results in higher fluxes. Overall, a combination of FaSSIF in the donor phase and BSA in the receiver phase facilitates improved experimental output. |
|---|---|
| Item Description: | Available online 17 October 2011 Gesehen am 12.07.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1873-3476 |
| DOI: | 10.1016/j.ijpharm.2011.10.026 |